Furthermore, we established a therapeutic model by administering an anti-PTX3 antibody [WHC-001; a neutralizing antibody that binds to PTX3, preventing its interaction with CD44 [29]] to evaluate whether blocking PTX3 in the tumor microenvironment can mitigate stroma-mediated tumor growth. The gene discussed is CD44; the disease is neoplasm.